Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Holds Its Ground On Genzyme Bid

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.

You may also be interested in...



Genzyme Jumps First Consent Decree Hurdle

Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.

Genzyme Jumps First Consent Decree Hurdle

Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.

Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.

Related Content

Topics

UsernamePublicRestriction

Register

PS071373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel